RXRX — Recursion Pharmaceuticals, Inc. stock price, charts and financials

Latest market price

3.31

+0.13+4.09%

Overview Short InterestFilings

RXRXQT17Recursion Pharmaceuticals, Inc.·NASDAQ

Overview Short InterestFilings

3.31+4.09%

Earnings

Up 4.1% — Reported earnings — EPS beat by 17%, revenue missed by 60%.

High confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-1.20	Insider Own	4.56%	Shs Outstand	524.68M	Perf Week	8.52%

Market Cap	1.74B	Forward P/E	-	EPS next Y	-0.93	Insider Trans	-2.93%	Shs Float	408.73M	Perf Month	-16.41%

Enterprise Value	1.14B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	44.23%	Perf Quarter	-5.97%

Income	-560.00M	P/S	26.31	EPS this Y	22.92%	Inst Trans	-	Short Ratio	9.44	Perf Half Y	-20.81%

Sales	66.00M	P/B	1.69	EPS next Y	-0.41%	ROA	-41.79%	Short Interest	180.76M	Perf YTD	-19.07%

Book/sh	1.95	P/C	2.66	EPS next 5Y	-	ROE	-54.32%	52W High	7.18 -53.90%	Perf Year	-41.73%

Cash/sh	1.25	P/FCF	-	EPS past 3/5Y	-	ROIC	-47.11%	52W Low	2.77 19.49%	Perf 3Y	-74.77%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	23.31% 90.37%	Gross Margin	-34.44%	Volatility	4.85% 5.40%	Perf 5Y	-89.23%

Dividend TTM	-	EV/Sales	17.30	EPS Y/Y TTM	28.99%	Oper. Margin	-882.92%	ATR (14)	0.19	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	5.47	Sales Y/Y TTM	11.86%	Profit Margin	-844.46%	RSI (14)	54.22	Recom	2.60

Dividend Gr. 3/5Y	-	Current Ratio	5.47	EPS Q/Q	56.00%	SMA20	4.35%	Beta	1.08	Target Price	5.50

Payout	0.00%	Debt/Eq	0.06	Sales Q/Q	-60.00%	SMA50	0.08%	Rel Volume	1.03	Prev Close	3.18

Employees	600	LT Debt/Eq	0.05	Earnings	Aug 05	SMA200	-14.63%	Avg Volume	20.85M	Price	3.31

IPO Date	Apr 16, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.98% -60.06%	Net Debt/EBITDA	1.21	Volume	21,444,082	Change	4.09%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-14-26	Reiterated	Morgan Stanley	Equal Weight	$11 → $5.50
Dec-17-25	Reiterated	UBS		$11
Dec-17-25	Reiterated	Morgan Stanley	Equal Weight	$11
Dec-17-25	Upgrade	JP Morgan	Neutral → Overweight
Feb-28-25	Reiterated	Leerink Partners	Market Perform	$6.00
Sep-04-24	Reiterated	Needham	Buy	$11
Sep-03-24	Reiterated	KeyBanc	Overweight	$12
Sep-03-24	Reiterated	Jefferies	Hold	$6.00
Jun-26-24	Reiterated	KeyBanc	Overweight
Apr-18-22	Downgrade	B of A Securities	Buy → Neutral

Latest News

Aug-04-26

Aug-04-2608:00AM

Recursion to Participate in Upcoming Investor Conferencesglobenewswire.com

Jul-31-26

Jul-31-2604:30PM

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rulesglobenewswire.com

Jul-30-26

Jul-30-2604:30PM

3 Stocks With the Most Upside by the End of 2026fool.com

Jul-29-26

Jul-29-2606:46PM

Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Knowzacks.com

08:30AM

Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5thglobenewswire.com

Jul-27-26

Jul-27-2606:51PM

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Considerzacks.com

Jul-24-26

Jul-24-2610:00AM

A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headedgurufocus.com

Jul-21-26

Jul-21-2603:16AM

Amova Asset Management Americas Inc. Sells 801,804 Shares of Recursion Pharmaceuticals, Inc. $RXRXdefenseworld.net

Jul-20-26

Jul-20-2606:51PM

Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Knowzacks.com

Jul-14-26

Jul-14-2606:51PM

Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Todayzacks.com

Jul-11-26

Jul-11-2604:30PM

2 Beaten-Down Stocks That Still Aren't Worth Buyingfool.com

Jul-08-26

Jul-08-2606:51PM

Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Marketzacks.com

09:35AM

3 Cancer Stocks to Watch as Oncology Innovation Accelerateszacks.com

Jul-05-26

Jul-05-2606:03AM

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Boughtfool.com

Jul-04-26

Jul-04-2609:21AM

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?fool.com

Company

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	66	75	59	44	40	10	3	2
Cost of Goods Sold Incl. D&A	89	121	45	43	48	0	0	46
Gross Profit	-22	-46	14	1	-9	10	3	-44
Selling, General and Administrative Excl. Other	158	177	178	111	82	58	25	19
Research and Development	421	425	314	241	156	135	63	46
Other Operating Expense	-17	0	1	-1	-1	0	0	-1
Operating Income	-585	-648	-479	-350	-246	-183	-85	-62
Interest Expense	1	2	2	0	0	3	1	1
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	23	5	16	18	6	-1	-1	1
Net Income Before Taxes	-564	-645	-465	-332	-239	-186	-87	-62
Income Taxes	-5	0	-1	-4	0	0	0	0
Consolidated Net Income	-560	-645	-464	-328	-239	-186	-87	-63
Net Income From Continuing Operations	-560	-645	-464	-328	-239	-186	-87	-62
Net Income	-560	-645	-464	-328	-239	-186	-87	-63
EPS (Recurring)	-1.20	-1.44	-1.69	-1.58	-1.36	-1.05	-0.52	-0.37
EPS (Basic, Before Extraordinaries)	-1.20	-1.44	-1.69	-1.58	-1.36	-1.05	-0.52	-0.37
EPS (Diluted)	-1.20	-1.44	-1.69	-1.58	-1.36	-1.05	-0.52	-0.37
EBITDA	-480	-559	-427	-308	-228	-175	-82	-58
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	26.53	24.38	31.39	46.61	33.92	291.21	—	—
Gross Margin	-33.33	-61.33	23.73	2.27	-22.50	100.00	100.00	-2,200.00
Operating Margin	-886.36	-864.00	-811.86	-795.45	-615.00	-1,830.00	-2,833.33	-3,100.00
Net Margin	-848.48	-860.00	-786.44	-745.45	-597.50	-1,860.00	-2,900.00	-3,150.00
Shares Outstanding	529	447	274	208	176	170	166	166
Market Capitalization	1,751	1,828	1,852	2,051	1,357	2,912	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Borgeson Blake	Director	Jul 07 '26	Sale	3.96	40,000	158,500	6,218,287	Jul 09
Bumpus Namandje	Director	Jun 18 '26	Sale	3.18	3,963	12,602	127,632	Jun 22
Gibson Christopher	Director	Jun 05 '26	Sale	3.62	40,000	144,800	883,735	Jun 05
Khan Najat	CEO and President	Jun 05 '26	Sale	3.58	23,588	84,459	2,175,796	Jun 05
Bumpus Namandje	Director	Jun 03 '26	Sale	3.54	4,386	15,526	43,171	Jun 04
Borgeson Blake	Director	Jun 02 '26	Sale	3.68	30,000	110,400	6,169,863	Jun 04
Gibson Christopher	Director	May 22 '26	Sale	3.08	40,000	123,200	883,735	May 27
Gibson Christopher	Director	May 07 '26	Sale	3.37	40,000	134,800	926,556	May 08
Borgeson Blake	Director	May 05 '26	Sale	3.52	30,000	105,600	6,199,863	May 07
Gibson Christopher	Director	Apr 22 '26	Sale	3.61	40,000	144,400	906,556	Apr 24
Borgeson Blake	Director	Apr 07 '26	Sale	3.10	30,000	93,000	6,229,863	Apr 08
Gibson Christopher	Director	Apr 07 '26	Sale	3.10	40,000	124,000	906,556	Apr 08
Gibson Christopher	Director	Mar 23 '26	Sale	3.25	40,000	130,000	906,556	Mar 25
Taylor Ben R	Chief Financial Officer	Mar 17 '26	Sale	3.39	7,956	26,971	1,180,318	Mar 18
Khan Najat	CEO and President	Mar 09 '26	Sale	3.35	28,298	94,660	2,262,085	Mar 11

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.